Joseph Jessica, Gotora Tendai, Erlwanger Alison S, Mushavi Angela, Zizhou Simukai, Masuka Nyasha, Boeke Caroline E, Mangwiro Alexio-Zambezi
*Clinton Health Access Initiative, Boston, MA; †Clinton Health Access Initiative, Harare, Zimbabwe; and ‡Ministry of Health and Child Care, Harare, Zimbabwe.
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S190-S197. doi: 10.1097/QAI.0000000000001341.
INTRODUCTION: Scale-up of Option B+ in Zimbabwe has increased antiretroviral therapy (ART) coverage but patient loss-to-follow-up remains high; thus, effective strategies to improve retention in care are needed. Evidence for Elimination, a cluster randomized controlled trial, evaluated the impact of point-of-care (POC) CD4 testing with CD4 count-specific adherence counseling on rates of retention among 1150 HIV-positive pregnant women initiating ART in Zimbabwe. METHODS: Thirty-two primary care health facilities were randomized to offer either standard-of-care (SOC) or POC CD4 testing plus CD4-specific counseling to clients (POC Plus). The primary outcome was the proportion of HIV-positive pregnant women retained on ART after 12 months, calculated by cluster-adjusted proportions, unadjusted and adjusted relative risks (RR and aRR, respectively). RESULTS: Retention in care 12 months after initiation was 50.7% and 54.5% in the POC Plus and SOC arms, respectively (RR 0.93, 95% confidence interval [CI]: 0.78 to 1.11; aRR 0.91, 95% CI: 0.77 to 1.07). Although considered not retained, 9.7% transferred to another facility and 0.2% died. Most women, 95.3% in POC Plus and 92.9% in SOC, initiated ART within 1 month of antenatal booking (RR 1.03, 95% CI: 0.97 to 1.08). DISCUSSION: Although patient retention was similar in both arms, women in the POC Plus arm were more likely to have received a CD4 test at booking and a repeat CD4 test later in care. CD4 is no longer required for treatment initiation but is still recommended in national guidelines and is of value in clinical management. Further work is needed to identify effective strategies to increase patient retention in ART care.
引言:在津巴布韦扩大“选项B+”方案已提高了抗逆转录病毒疗法(ART)的覆盖率,但患者失访率仍然很高;因此,需要有效的策略来提高治疗依从性。“消除证据”是一项整群随机对照试验,评估了即时检验(POC)CD4检测及针对CD4计数的依从性咨询对津巴布韦1150名开始接受ART治疗的HIV阳性孕妇治疗依从率的影响。 方法:32个初级保健卫生机构被随机分为两组,一组为客户提供标准治疗(SOC),另一组提供POC CD4检测及针对CD4的咨询(POC Plus)。主要结局是12个月后仍接受ART治疗的HIV阳性孕妇比例,通过整群调整比例、未调整和调整后的相对风险(分别为RR和aRR)计算得出。 结果:开始治疗12个月后的治疗依从率在POC Plus组和SOC组分别为50.7%和54.5%(RR 0.93,95%置信区间[CI]:0.78至1.11;aRR 0.91,95% CI:0.77至1.07)。虽然被视为未坚持治疗,但9.7%的患者转至另一机构,0.2%的患者死亡。大多数女性,POC Plus组为95.3%,SOC组为92.9%,在产前登记后1个月内开始接受ART治疗(RR 1.03,95% CI:0.97至1.08)。 讨论:虽然两组的患者治疗依从率相似,但POC Plus组的女性在登记时更有可能接受CD4检测,并在后续治疗中接受重复CD4检测。开始治疗不再需要CD4检测,但国家指南仍推荐进行检测,且其在临床管理中具有价值。需要进一步开展工作,以确定提高患者接受ART治疗依从性的有效策略。
Cochrane Database Syst Rev. 2010-3-17
J Acquir Immune Defic Syndr. 2017-6-1
PLOS Glob Public Health. 2021-10-13
J Glob Health. 2022